Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Adc Therapeutics Sa (ADCT)

Adc Therapeutics Sa (ADCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire - Thu Jun 18, 9:00AM CDT

NEW YORK , June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT).  Such investors are advised to...

ADCT : 1.0900 (-1.80%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire - Thu Jun 11, 9:00AM CDT

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates PR Newswire - Mon May 4, 6:30AM CDT

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability Barchart - Sun May 3, 4:00PM CDT

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability Barchart - Sat May 2, 4:00PM CDT

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability Barchart - Fri May 1, 4:02PM CDT

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire - Fri May 1, 3:05AM CDT

LAUSANNE, Switzerland , May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 PR Newswire - Mon Apr 27, 6:30AM CDT

LAUSANNE, Switzerland , April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Announces New Employee Inducement Grant PR Newswire - Wed Apr 1, 3:05PM CDT

LAUSANNE, Switzerland , April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 1.0900 (-1.80%)
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update PR Newswire - Tue Mar 10, 6:30AM CDT

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

ADCT : 1.0900 (-1.80%)

Barchart Exclusives

Dear MicroStrategy Stock Fans, Mark Your Calendars for July 4 Barchart - Sat Jun 20, 11:00AM CDT
Strategy investors are closely watching the July 4 CLARITY Act deadline, which could reshape crypto regulation and influence bitcoin-linked stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.